Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
2.
Cell Mol Neurobiol ; 44(1): 31, 2024 Apr 01.
Article in English | MEDLINE | ID: mdl-38557942

ABSTRACT

Glioblastoma multiforme (GBM) is the most predominant and malignant primary brain tumor in adults. Thymic stromal lymphopoietin (TSLP), a cytokine primarily generated by activated epithelial cells, has recently garnered attention in cancer research. This study was aimed to elucidate the significance of TSLP in GBM cells and its interplay with the immune system, particularly focused on granulocyte neutrophils. Our results demonstrate that the tumor produces TSLP when stimulated with epidermal growth factor (EGF) in both the U251 cell line and the GBM biopsy (GBM-b). The relevance of the TSLP function was evaluated using a 3D spheroid model. Spheroids exhibited increased diameter, volume, and proliferation. In addition, TSLP promoted the generation of satellites surrounding the main spheroids and inhibited apoptosis in U251 treated with temozolomide (TMZ). Additionally, the co-culture of polymorphonuclear (PMN) cells from healthy donors with the U251 cell line in the presence of TSLP showed a reduction in apoptosis and an increase in IL-8 production. TSLP directly inhibited apoptosis in PMN from GBM patients (PMN-p). Interestingly, the vascular endothelial growth factor (VEGF) production was elevated in PMN-p compared with PMN from healthy donors. Under these conditions, TSLP also increased VEGF production, in PMN from healthy donors. Moreover, TSLP upregulated programed death-ligand 1 (PDL-1) expression in PMN cultured with U251. On the other hand, according to our results, the analysis of RNA-seq datasets from Illumina HiSeq 2000 sequencing platform performed with TIMER2.0 webserver demonstrated that the combination of TSLP with neutrophils decreases the survival of the patient. In conclusion, our results position TSLP as a possible new growth factor in GBM and indicate its modulation of the tumor microenvironment, particularly through its interaction with PMN.


Subject(s)
Glioblastoma , Thymic Stromal Lymphopoietin , Adult , Humans , Cells, Cultured , Cytokines/metabolism , Neutrophils/metabolism , Tumor Microenvironment , Vascular Endothelial Growth Factor A
3.
Immunology ; 153(2): 225-237, 2018 02.
Article in English | MEDLINE | ID: mdl-28888033

ABSTRACT

γδ T cells are non-conventional, innate-like T cells, characterized by a restricted T-cell receptor repertoire. They participate in protective immunity responses against extracellular and intracellular pathogens, tumour surveillance, modulation of innate and adaptive immune responses, tissue healing, epithelial cell maintenance and regulation of physiological organ function. In this study, we investigated the role of neutrophils during the activation of human blood γδ T cells through CD3 molecules. We found that the up-regulation of CD69 expression, and the production of interferon-γ and tumour necrosis factor-α induced by anti-CD3 antibodies was potentiated by neutrophils. We found that inhibition of caspase-1 and neutralization of interleukin-18 did not affect neutrophil-mediated modulation. By contrast, the treatment with serine protease inhibitors prevented the potentiation of γδ T-cell activation induced by neutrophils. Moreover, the addition of elastase to γδ T-cell culture increased their stimulation, and the treatment of neutrophils with elastase inhibitor prevented the effect of neutrophils on γδ T-cell activation. Furthermore, we demonstrated that the effect of elastase on γδ T cells was mediated through the protease-activated receptor, PAR1, because the inhibition of this receptor with a specific antagonist, RWJ56110, abrogated the effect of neutrophils on γδ T-cell activation.


Subject(s)
Leukocyte Elastase/immunology , Lymphocyte Activation , Neutrophil Activation/immunology , Neutrophils/immunology , Receptors, Antigen, T-Cell, gamma-delta/immunology , T-Lymphocytes/immunology , Antigens, CD/immunology , Antigens, Differentiation, T-Lymphocyte/immunology , CD3 Complex/immunology , Humans , Interferon-gamma/immunology , Lectins, C-Type/immunology , Neutrophils/cytology , Receptor, PAR-1/immunology , T-Lymphocytes/cytology , Tumor Necrosis Factor-alpha/immunology
4.
Cell Mol Immunol ; 12(6): 669-80, 2015 Nov.
Article in English | MEDLINE | ID: mdl-25502213

ABSTRACT

Circulating monocytes (Mos) may continuously repopulate macrophage (MAC) or dendritic cell (DC) populations to maintain homeostasis. MACs and DCs are specialized cells that play different and complementary immunological functions. Accordingly, they present distinct migratory properties. Specifically, whereas MACs largely remain in tissues, DCs are capable of migrating from peripheral tissues to lymphoid organs. The aim of this work was to analyze the expression of the fractalkine receptor (CX3CR1) during the monocytic differentiation process. Freshly isolated Mos express high levels of both CX3CR1 mRNA and protein. During the Mo differentiation process, CX3CR1 is downregulated in both DCs and MACs. However, MACs showed significantly higher CX3CR1 expression levels than did DC. We also observed an antagonistic CX3CR1 regulation by interferon (IFN)-γ and interleukin (IL)-4 during MAC activation through the classical and alternative MAC pathways, respectively. IFN-γ inhibited the loss of CX3CR1, but IL-4 induced it. Additionally, we demonstrated an association between CX3CR1 expression and apoptosis prevention by soluble fractalkine (sCX3CL1) in Mos, DCs and MACs. This is the first report demonstrating sequential and differential CX3CR1 modulation during Mo differentiation. Most importantly, we demonstrated a functional link between CX3CR1 expression and cell survival in the presence of sCX3CL1.


Subject(s)
Dendritic Cells/cytology , Macrophages/cytology , Monocytes/cytology , Receptors, Chemokine/genetics , Apoptosis/drug effects , CX3C Chemokine Receptor 1 , Cell Differentiation/drug effects , Cell Movement/drug effects , Cell Survival/drug effects , Dendritic Cells/drug effects , Dendritic Cells/immunology , Gene Expression Regulation , Humans , Interferon-gamma/genetics , Interferon-gamma/immunology , Interferon-gamma/pharmacology , Interleukin-4/genetics , Interleukin-4/immunology , Interleukin-4/pharmacology , Macrophages/drug effects , Macrophages/immunology , Monocytes/drug effects , Monocytes/immunology , Organ Specificity , Primary Cell Culture , Receptors, Chemokine/immunology , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL